Art Biktarvy denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for art biktarvy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues an Experimental Denial for Biktarvy — and Why This Is Appealable

A denial characterizing Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) as "experimental or investigational" is almost certainly incorrect as a factual matter. Biktarvy holds full FDA approval for the treatment of HIV-1 infection in adults and certain pediatric patients, and it is recognized in major HIV treatment guidelines as a recommended first-line regimen. This type of denial frequently results from a coding error, a formulary system glitch, or a policy that was not updated after FDA approval.

Because this denial rests on a factually incorrect premise, it is among the most straightforward to overturn on appeal.

## The Federal Appeal Framework

• ACA §2719 External Review: Non-grandfathered plans must offer independent external review. The filing deadline is typically around 180 days from the denial notice — check your letter for the exact date.
• ERISA §503 (employer-sponsored plans): Requires written explanation of the specific plan provisions and the clinical evidence basis used to classify the drug as experimental.
• Expedited review: If a continued gap in HIV therapy would seriously jeopardize your health, invoke expedited review in writing simultaneously with your internal appeal.

## What to Gather

1. FDA approval documentation — the FDA product label and approval letter for Biktarvy are publicly available. Print and attach them. The label's approval date directly refutes the experimental classification. 2. Relevant guideline reference — your prescriber may reference the applicable DHHS (Department of Health and Human Services) HIV treatment guidelines, which list Biktarvy among recommended regimens. Cite the guideline organization; do not quote specific numbers from it. 3. Prescriber medical-necessity letter — should state the diagnosis (HIV-1 infection), confirm FDA-approved indication, and explain why Biktarvy was selected for this patient. 4. BCBS's experimental/investigational policy — obtain the plan's published criteria for classifying a drug as experimental and show, point by point, that Biktarvy does not satisfy any of those criteria. 5. Diagnosis confirmation — recent lab results or chart notes confirming HIV-1 diagnosis and current treatment status.

## Criteria-Mapping Structure

| BCBS "Experimental" Criterion | Why Biktarvy Does NOT Meet It | |---|---| | [Paste each criterion from the plan's experimental/investigational policy] | [Cite FDA approval, label, and guideline recognition] |

## Next Steps

File a written internal appeal with the FDA label attached. Request that the plan's medical director review the denial, as the factual error should be resolvable at that level. If the plan upholds the denial despite FDA approval documentation, escalate immediately to external review — independent reviewers are very unlikely to sustain an experimental classification for a fully FDA-approved, guideline-recommended regimen.